trending Market Intelligence /marketintelligence/en/news-insights/trending/UaCx7VsCIcmNYKLioMw-NA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Sanofi's $2.5B acquisition of I-O company Synthorx gets antitrust clearance

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Sanofi's $2.5B acquisition of I-O company Synthorx gets antitrust clearance

Sanofi's $2.5 billion acquisition of immuno-oncology company Synthorx Inc. received antitrust clearance.

The Paris-based drugmaker said the waiting period under the Hart-Scott-Rodino Act applicable to the deal has expired.

On Dec. 23, 2019, Sanofi started a tender offer to acquire all of Synthorx's shares at $68 each.

La Jolla, Calif.-based Synthorx is developing therapies intended to treat cancer and autoimmune disorders through its proprietary technology. The company's lead asset, THOR-707, is being evaluated as a potential treatment of multiple solid tumor types as a stand-alone therapy and in combination with immune checkpoint inhibitors.